Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 2
1957 3
1959 3
1960 6
1963 1
1964 1
1965 2
1968 1
1971 1
1975 5
1976 3
1977 1
1978 2
1979 4
1980 16
1981 13
1982 4
1983 8
1984 11
1985 10
1986 9
1987 7
1988 12
1989 13
1990 13
1991 11
1992 5
1993 3
1994 4
1995 4
1996 8
1997 2
1998 2
1999 5
2000 3
2001 1
2002 1
2005 3
2006 1
2007 3
2008 4
2010 1
2011 2
2012 1
2015 1
2016 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Results by year

Filters applied: . Clear all
Page 1
The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
Mikkola A, Ruutu M, Aro J, Rannikko S, Salo J. Mikkola A, et al. Ann Chir Gynaecol. 1999;88(1):18-21. Ann Chir Gynaecol. 1999. PMID: 10230677 Review.
Oral estrogen therapy is as effective as orchiectomy in terms of cancer inhibitory effect, but its acceptance as primary hormonal treatment is overshadowed by an increased risk of cardiovascular complications. Parenteral estrogen, polyestradiol phosphate (PEP), is e …
Oral estrogen therapy is as effective as orchiectomy in terms of cancer inhibitory effect, but its acceptance as primary hormonal treatment …
Clinical pharmacology of polyestradiol phosphate.
Gunnarsson PO, Norlén BJ. Gunnarsson PO, et al. Prostate. 1988;13(4):299-304. doi: 10.1002/pros.2990130405. Prostate. 1988. PMID: 3217277
The results of the present studies demonstrate that intramuscular injections of polyestradiol phosphate (PEP) produce not only considerably increased estrogen concentration in plasma but also maintain the same estrone/estradiol ratio as in normal men. ...
The results of the present studies demonstrate that intramuscular injections of polyestradiol phosphate (PEP) produce not only …
Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
Kalland T, Haukaas S. Kalland T, et al. Invest Urol. 1981 May;18(8):437-9. Invest Urol. 1981. PMID: 7228576
We evaluated the effect of treatment of patients with prostatic cancer with estramustine phosphate or the combination diethylstilbestrol-polyestradiol phosphate on the natural killer cell activity in peripheral blood. Although estramustine phosphate did not affect n …
We evaluated the effect of treatment of patients with prostatic cancer with estramustine phosphate or the combination diethylstilbestrol- …
Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma.
Lindstedt E. Lindstedt E. Scand J Urol Nephrol Suppl. 1980;55:95-7. Scand J Urol Nephrol Suppl. 1980. PMID: 6938044
Polyestradiol phosphate is a polymeric ester of estradiol -17 beta and phosphoric acid. ...It is suggested that polyestradiol phosphate is as effective as other estrogen therapy for prostatic carcinoma and that the combination with ethinylestradiol is …
Polyestradiol phosphate is a polymeric ester of estradiol -17 beta and phosphoric acid. ...It is suggested that polyestradi …
Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
Aro J, Ruutu M, Juusela H, Hansson E, Permi J. Aro J, et al. Ann Chir Gynaecol Suppl. 1993;206:5-8. Ann Chir Gynaecol Suppl. 1993. PMID: 8291869 Clinical Trial.
The clinical efficacy, cardiovascular complications and mortality of polyestradiol phosphate (PEP) 160 mg/month i.m. were compared with the luteinizing hormone releasing hormone (LHRH) analog, buserelin, in a prospective, randomised multicentre study including 147 p …
The clinical efficacy, cardiovascular complications and mortality of polyestradiol phosphate (PEP) 160 mg/month i.m. were comp …
Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.
Henriksson P, Eriksson A, Stege R, Collste L, Pousette A, von Schoultz B, Carlström K. Henriksson P, et al. Prostate. 1988;13(3):257-61. doi: 10.1002/pros.2990130308. Prostate. 1988. PMID: 3211807
Thirty-eight patients with cancer of the prostate were treated with strict parenteral estrogen in the form of monthly polyestradiol phosphate injections--160 mg, 240 mg, and 320 mg--in this nonrandomized study. ...
Thirty-eight patients with cancer of the prostate were treated with strict parenteral estrogen in the form of monthly polyestradiol …
Polyestradiol phosphate: a preliminary evaluation of its effect on breast carcinoma.
Ostrowski MJ, Jackson AW. Ostrowski MJ, et al. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1803-7. Cancer Treat Rep. 1979. PMID: 393380 Clinical Trial.
The effect of polyestradiol phosphate (Estradurin), a long-acting estrogen preparation given im, was assessed in 24 elderly postmenopausal patients with stage II or III primary or recurrent breast carcinoma. ...
The effect of polyestradiol phosphate (Estradurin), a long-acting estrogen preparation given im, was assessed in 24 elderly po …
214 results